ACADIA Pharmaceuticals Targets $1.7B Sales by 2028, Teases Key Phase 2 Data in 2025 [Yahoo! Finance]
ACADIA Pharmaceuticals Inc. (ACAD)
Last acadia pharmaceuticals inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-irhome
Company Research
Source: Yahoo! Finance
ACADIA Pharmaceuticals (NASDAQ:ACAD) executives outlined the company's revenue outlook, commercial priorities for its two marketed products, and upcoming clinical catalysts during a fireside chat at the TD Health Care Conference. 2028 net sales outlook driven by NUPLAZID and DAYBUE Management reiterated guidance projecting $1.7 billion in net sales by 2028 , split between NUPLAZID at $1.0 billion and DAYBUE at $700 million ? The Head Fake: Buying the Chinese Stocks Post-Ruling Dip For NUPLAZID, the company's 2026 guidance midpoint assumes approximately 12% growth , with a similar growth rate assumed for 2027. Executives said their confidence in a “change in trajectory” is supported by expectations for acceleration in the back half of 2025, noting the company recently reported 18% growth in fourth-quarter MBRx . They attributed momentum to a focused marketing strategy—including direct-to-consumer efforts to raise awareness of hallucinations and delusions—and a revamped field f
Show less
Read more
Impact Snapshot
Event Time:
ACAD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACAD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACAD alerts
High impacting ACADIA Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
ACAD
News
- Acadia Faces EU Setback On Trofinetide As Valuation Signals Diverge [Yahoo! Finance]Yahoo! Finance
- Is It Time To Revisit ACADIA Pharmaceuticals (ACAD) After Recent Share Price Weakness? [Yahoo! Finance]Yahoo! Finance
- ACADIA Pharmaceuticals (ACAD) had its price target raised by JPMorgan Chase & Co. from $31.00 to $34.00. They now have an "overweight" rating on the stock.MarketBeat
- Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors [Yahoo! Finance]Yahoo! Finance
- Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of DirectorsBusiness Wire
ACAD
Earnings
- 2/25/26 - Beat
ACAD
Sec Filings
- 3/5/26 - Form 8-K
- 2/26/26 - Form SCHEDULE
- 2/26/26 - Form 10-K
- ACAD's page on the SEC website